Perrigo (PRGO) Q1 Earnings Beat Estimates
Perrigo (PRGO) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.29 per share a year ago.
Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock?
PRGO's first-quarter top line is likely to have been impacted by exited businesses and product lines, and unfavorable currency movements.
Perrigo (PRGO) Earnings Expected to Grow: Should You Buy?
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo: Opill Shows Where The Company Wants To Be
Perrigo's transformation from a low-margin generics manufacturer to a branded consumer self-care company hinges on the success of products like Opill and Mederma. Despite short-term revenue declines, Perrigo's margin expansion and cost-saving initiatives show promise for long-term growth and strategic focus. The company's financial health is under pressure, with high leverage and volatile infant formula business posing significant risks.
Investing in Perrigo (PRGO)? Don't Miss Assessing Its International Revenue Trends
Review Perrigo's (PRGO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Perrigo Company plc (PRGO) 2025 Investor Day (Transcript)
Perrigo Company plc (NYSE:PRGO ) Perrigo 2025 Investor Day February 28, 2025 8:00 AM ET Company Participants Brad Joseph - Vice President, Investor Relations Patrick Lockwood-Taylor - President and Chief Executive Officer Eduardo Bezerra - Executive Vice President and Chief Financial Officer Triona Schmelter - President of CSCA Roberto Khoury - President of CSCI Ron Janish - Head of Global Supply Chain Abbie Lennox - Chief Scientific Officer David Ball - Chief Marketing & Digital Officer Charles Atkinson - General Counsel Conference Call Participants Keith Devas - Jefferies Susan Anderson - Canaccord Korinne Wolfmeyer - Piper Sandler Chris Schott - JPMorgan Daniel Biolsi - Hedgeye Operator Welcome to Perrigo's 2025 Investor Day. [Operator Instructions] Brad Joseph Good morning, good afternoon and good evening.
Perrigo's Q4 Earnings Beat Estimates, Revenues Decline Y/Y
PRGO reports mixed Q4 2024 results. The decline in the company's top line is due to the loss of sales stemming from exited businesses and product lines.
Perrigo (PRGO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Perrigo (PRGO) Q4 Earnings Beat Estimates
Perrigo (PRGO) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.86 per share a year ago.
Countdown to Perrigo (PRGO) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for Perrigo (PRGO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect
PRGO's fourth-quarter top line is likely to have benefited from higher net price realization for its products through strategic price increases.
Perrigo Paves The Way For Recovery With Margin Focus
Perrigo is a focused OTC consumer healthcare player, slimming down operations and enhancing margins under new management, with a 4.6% dividend yield. Despite short-term pressures from a weak cold-and-flu season and infant formula production issues, PRGO is positioned for recovery and growth by 2026. The company is exploring new markets with a 'disruptive growth' team, focusing on women's health and GLP-1 side effect relief, aiming for mid-single-digit growth.
